← Leaderboards
Russell C Hovey
University Of California At Davis
$203,916
Attributed
$390,892
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $206.6K · FY2006–23$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$390,892 · 2
By mechanism
R21$373,952 · 1
P20$16,940 · 1
Top collaborators
- Cheemeng Tan2 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Aijun Wang$6,380,053
- Randy Carney$5,113,600
- Cheemeng Tan$3,731,822
- Jing Hong Wang$12,171,384
- Mansoor M. Amiji$9,305,730
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsAnti-CancerAqueousAttenuatedAutolysisBacteriaBiomaterial CompatibilityBrca1 GeneBreastBreast Cancer CellBreast Cancer Cell LineBreast Cancer GeneBreast Cancer ModelBreast Cancer TherapyBreast Cancer TreatmentCancer CellCancer ImmunotherapyCancer TherapyCd47 GeneCell LineCell MembraneCellsClustered Regularly Interspaced Short Palindromic RepeatsAntagonist
Grant awards (3)
Engineering non-proliferating-but-active (NPBA) probiotic for breast-cancer gene therapy$167,325
R21 · FY2023 · CA
Engineering non-proliferating-but-active (NPBA) probiotic for breast-cancer gene therapy$206,627
R21 · FY2022 · CA
MODELING HUMAN BREAST CANCER IN SWINE$16,940
P20 · FY2006 · RR · contact PI